Marengo Earns ESMO Oral Slot for Phase II Cancer Data
CAMBRIDGE, Mass., July 20, 2026 Marengo Therapeutics has announced that updated Phase II clinical data from its investigational immunotherapy...
Phase II trial
Advertisement
Nuvation Bio Expands Safusidenib Program with Strong Phase II Data
NEW YORK, July 20, 2026 Nuvation Bio Inc. has announced positive updated Phase II clinical data for safusidenib, its...
InnoCare Reports Positive Phase II Soficitinib Results
Beijing, July 16, 2026 InnoCare Pharma announced that the Phase II portion of its adaptive Phase II/III clinical trial...
Boehringer Ingelheim Advances BI 3034701 into Phase II Obesity Trial
INGELHEIM, Germany, July 16, 2026 Boehringer Ingelheim has initiated a Phase II clinical trial evaluating BI 3034701, an investigational...
Cardiol Therapeutics Publishes Recurrent Pericarditis Phase II Data
TORONTO, Ontario, July 14, 2026 Cardiol Therapeutics Inc. has announced the publication of its Phase II MAvERIC clinical trial...
Advertisements
Grünenthal Receives Dual FDA Designations for Tegacorat in DMD
AACHEN, Germany, July 8, 2026 Grünenthal has announced that the U.S. Food and Drug Administration (FDA) has granted both...
HUTCHMED Wins NMPA Approval for ORPATHYS® in Gastric Cancer
Hong Kong, Shanghai & Florham Park, N.J., July 2, 2026 HUTCHMED has achieved a major regulatory milestone after the...
Kowa Gains FDA Breakthrough Status for K-808 in PBC
NAGOYA, Japan, June 30, 2026 Kowa Company, Ltd. has achieved a significant regulatory milestone after the U.S. Food and...
Ipsen Acquires Memo Therapeutics to Expand Rare Disease Pipeline
PARIS, France & SCHLIEREN/ZURICH, Switzerland, July 1, 2026 Ipsen has announced a definitive agreement to acquire Memo Therapeutics AG,...
HUTCHMED Reports Strong Phase II Fanregratinib Data in ICC
HONG KONG, SHANGHAI & FLORHAM PARK, N.J., June 25, 2026 HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) announced that pivotal Phase II registration...
Advertisement
